> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Draft Guidance on Biosimilar Container Closure Design
- URL: https://www.fdaweb.com/draft-guidance-on-biosimilar-container-closure-design/
- Published: 2026-07-31T12:00:00.000Z
- Updated: 2026-09-14T13:44:16.000Z
- Author: David McFarland
- Tags: Biologics, #legacy-id-D5161556

A new FDA draft guidance is outlining how sponsors should develop and evaluate container closure systems and device components used with biosimilar and interchangeable biosimilar products, providing a clearer framework for demonstrating that design differences from reference products do not compromise safety or effectiveness.

The [document](https://www.fda.gov/media/193917/download?ref=fdaweb.com) focuses on therapeutic protein biosimilars and addresses container closure systems, such as vials and prefilled syringes, as well as device constituent parts including autoinjectors and injector pens. FDA says it expands and clarifies previous recommendations on the data and studies needed to support applications submitted under the abbreviated biosimilar pathway.

Under the guidance, sponsors are expected to carefully compare the container closure systems and device constituent parts of a proposed biosimilar with its reference product, while ensuring the proposed product does not introduce a new condition of use, dosage form, strength, or route of administration. For products that incorporate delivery devices, FDA recommends a stepwise evaluation of the user interface, including physical comparisons of the device, comparative task analyses, and side-by-side reviews of labeling and instructions for use. Sponsors should identify design differences, determine whether those differences could affect "critical tasks" performed by patients or healthcare providers, and classify the differences as either minor or more significant.

The agency says that when only minor design differences exist, comparative analyses alone may be sufficient to support approval. However, if design changes could affect how users administer the product, FDA may require additional evidence, including human factors studies, in vitro testing, or other scientific data to demonstrate that the differences do not create new safety risks or undermine a determination of biosimilarity or interchangeability.

FDA also says id biosimilar applicants may seek approval for a different container closure system and device constituent parts than the reference product — for example, a prefilled syringe or autoinjector instead of a vial — provided the product continues to meet statutory standards for biosimilarity and does not alter approved conditions of use. Interchangeable biosimilars with these differences, however, are generally expected to require additional data to demonstrate that users can safely substitute the product without intervention from the prescribing healthcare provider.